Leerink Partners initiates Outperform coverage on ABSI with $12 price target

 

• Analyst initiation drove +15.74% gain on June 4, 2026, implying over 100% upside from ~$6 levels.
• Highlights lead asset ABS-201 (anti-PRLR antibody) for androgenetic alopecia and endometriosis.
• Upcoming clinical readouts for ABS-201 expected in H1/H2 2026, building on positive Phase 1 safety data.
• Follows Jefferies Global Healthcare Conference presentation on June 3 and sustained positive analyst sentiment.
• Absci's AI-driven platform for biologics and strong cash runway into 2028 cited as key strengths.

https://finviz.com/stock?t=ABSI&p=d